Latitude Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-2,893
Closed -$377K 210
2022
Q1
$377K Buy
2,893
+965
+50% +$126K 0.08% 224
2021
Q4
$294K Hold
1,928
0.08% 229
2021
Q3
$312K Buy
+1,928
New +$324K 0.1% 200

Other funds holding IBB

Latitude Advisors's IBB Position: Q2 2022 in Review

Latitude Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 2,893 shares — an estimated $377K sold.

Latitude Advisors first reported a position in IBB in Q3 2021 and held it in 3 quarters. The position peaked at $377K in Q1 2022. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

  • Latitude Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
  • Latitude Advisors sold 2,893 iShares Biotechnology ETF shares in Q2 2022, an estimated $377K.
  • Latitude Advisors first reported a position in iShares Biotechnology ETF in Q3 2021 and held it in 3 quarters.
  • Latitude Advisors's iShares Biotechnology ETF position peaked at $377K in Q1 2022.
  • 858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Latitude Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.